Prescribe only as part of an overall plan for managing obesity in adults who have:
BMI of 28.0 kg/m2 or more with associated risk factors, or
BMI of 30.0 kg/m2 or more.
Continue treatment for longer than 3 months only if the person has lost at least 5% of their initial body weight since starting drug treatment
Continue for longer than 12 months only after discussing potential benefits and limitations with the patient.
Pack
42 capsule
84 capsule
120 capsule
Pack
84 capsule

Note variation in licensing of different brands of liraglutide

Saxenda brand is licensed for obesity indication
Recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults who meet the NICE criteria (TA664)
Primary care prescribers should NOT accept prescribing responsibility.
Prescribing must be initiated and maintained by a specialist multidisciplinary tier 3 weight management service.
Pack
5 pre-filled disposable injection
Pack
5 pre-filled disposable injection
3 pre-filled disposable injection

Wegovy brand is licensed for obesity indication

Recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults who meet the NICE criteria (TA875)

Primary care prescribers should NOT accept prescribing responsibility.

Prescribing must be initiated and maintained by a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4)

Pack
1 pre-filled disposable injection
Pack
1 pre-filled disposable injection
Pack
1 pre-filled disposable injection
Pack
1 pre-filled disposable injection
Pack
1 pre-filled disposable injection